Background-Although some familial cancer syndromes include biliary tract cancers (BTCs) (cancers of the gallbladder, intrahepatic and extrahepatic bile ducts, and ampulla of Vater), the few studies that have examined the relationships between family history of cancer (FHC) and BTCs have reported inconclusive findings. The objective of this study was to investigate the associations of FHC with risk of BTC in the Biliary Tract Cancers Pooling Project (BiTCaPP).
Introduction
Biliary tract cancers (BTCs), including gallbladder (GBC), intrahepatic (IHBDC) and extrahepatic (EHBDC) bile duct, and ampulla of Vater (AVC) cancers, have a poor prognosis (1) . Previous studies found associations of familial cancer syndromes (familial adenomatous polyposis, Lynch syndrome, neurofibromatosis type 1) with BTC risk, suggesting they may have a heritable component (2) .
While some studies suggest a higher risk of BTCs among individuals with a family history of cancer (FHC) compared to people without a FHC, most studies examined BTCs combined (3) or only at one anatomic site (4) (5) (6) or had small numbers of cases (3, (5) (6) (7) (8) . Also, it is unknown whether family history of gastrointestinal or hormonally-dependent cancers is associated with BTCs. We investigated associations of type of FHC with risk of BTC by anatomic site.
Materials and Methods
The Biliary Tract Cancers Pooling Project (BiTCaPP) combines data from 28 prospective studies involving over 2.8 million people. The National Cancer Institute has Office of Human Subjects Research Protection exemption for BiTCaPP. Contributing studies received institutional review board approval prior to data collection; participants gave written informed consent.
FHC was available from 12 BiTCaPP studies (Table 1) and was harmonized as: any FHC, first degree FHC, cancer history in a female relative, cancer history in a male relative, family history of gastrointestinal cancers (colorectum, esophagus, small intestine, stomach, liver, biliary tract, pancreas), and family history of hormonally-related cancers (breast, ovarian, prostate, endometrial/uterine). Exclusions were prevalent disease at baseline, missing person time, age at baseline, or case/non-case status and age <18 years at baseline.
Relationships between FHC and baseline characteristics were examined using χ 2 tests for categorical variables and t-tests for continuous variables. We used Cox proportional hazards regression models with age as the time scale and left truncation at recruitment to estimate HRs and 95% confidence intervals (CI) for associations between FHC and BTCs, adjusting for sex and race/ethnicity, with baseline hazard stratified by study. Analyses were repeated restricting to studies reporting cholecystectomy and to people without a history of cholecystectomy. To address concerns that FHC may be associated with history of cholecystectomy, and thereby bias results toward the null, we evaluated these relationships using logistic regression adjusting for baseline age, sex, and race/ethnicity. All tests were two-sided (α=0.05) and conducted using SAS software (Version 9.3, Cary, NC).
Results
Data were available for over 1.5 million people (58% of BiTCaPP) and 21,706,107 personyears (Table 1) . Participants averaged 60 years-old at baseline and were mostly non-Hispanic white with slightly more women than men ( Table 1 ). Compared with people without a FHC, people with a FHC were more likely to be women (59 vs. 53%, P<0.0001) and non-Hispanic white (87 vs. 79%, P<0.0001) and to have a college education (68 vs. 60%, P<0.0001). Differences in baseline age [mean (standard deviation) for with FHC vs. without FHC, P-value: 61 (8) vs. 60 (9), <0.0001] and history of diabetes or gallstones (with FHC vs. without FHC, P-value: 8 vs. 9%, <0.0001 for diabetes and 10 vs. 9%, <0.0001 for gallstones) between people with and without any FHC were statistically significant, but too small to be clinically meaningful. People with any FHC more frequently reported a cholecystectomy history [odds ratio (95% CI): 1.20 (1.18-1.21)].
Discussion
In the largest study to date, we examined associations of FHC and BTC risk by anatomic site. We observed no association of FHC with IHBDC or EHBDC and marginal, inverse associations with GBC and with AVC. To address the concern that associations of FHC with GBC may reflect informative censoring by cholecystectomy rather than a true association, we restricted FHC-GBC analyses to studies reporting cholecystectomy and to people not reporting a history of a cholecystectomy, which drove associations between FHC and GBC to the null. The association between family history of hormonally-related cancer (upper CI of 0.99) and AVC may represent a false positive finding among many comparisons.
While most previous studies reported FHC associated with higher risk of BTCs overall (3), GBC (4, 5, 7), EHBDC or IHBDC (6, 7), or AVC (7), one study using FHC from the Utah pedigree database reported statistically nonsignificant, lower risks of BTCs with FHC (8) . BiTCaPP was also predominantly comprised of non-Hispanic whites from the U.S. It is possible that the association of FHC with BTC risk may vary by population. Thus, FHC still may be an important predictor of BTC risk outside of the United States. Misclassification of self-reported FHC is possible but likely nondifferential.
In the largest prospective study, we found no associations between FHC and BTC risk. These results provide no support to the hypothesis that having a FHC is associated with higher BTC risk. As we were unable to examine associations of family history of BTCs with BTCs, the results do not preclude this potential association.
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